Molina RE

Language: Spanish
References: 9
Page: 39-41
PDF size: 168.53 Kb.

ABSTRACT

The diabetes mellitus is a main cause of chronic renal failure, the microproteinuria as an early and sensitive marker to the risk of future development of overt nephropathy and chronic renal failure. The microproteinuria control decrease the heart risk factor because it is a predictor of microangiopathic complications. Angiotensina II receptor antagonist (AIIAs) should be considered mandatory therapy in patients with diabetic nephropathy and should complement existing management strategies, such as reduced dietary protein intake, strict blood glucose control, and standard antihypertensive therapy.

REFERENCES

1. American Diabetes Association. Nephropathy in Diabetes Mellitus. Diabetes Care. Vol 27, supl 1, enero 2004

2. Caja Costarricense de Seguro Social. Plan de Atención a la Salud de las Personas. 2001-2006.

3. Donnelly R, Emslie-Smith AM, Gardner ID, Morris AD. Vascular complications of diabetes. BMJ 2000;320:1062-1066.

4. Grundy SM, Benjamin IJ, Burke GL, et al. Diabetes and Cardiovascular Disease. A Statement for Healthcare Professionals From the American Heart Association. Circulation 1999;100:1134-1146.

5. Ruilope LM, Segura J Losartan and other angiotensin II antagonists for nephropathy in type 2 diabetes mellitus: a review of the clinical trial evidence. Clin Ther. 2003 Dec;25(12):3044-64.

6. Turner RC, Millns H, Neil HAW, et al. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS:23). BMJ N 316 :823-828.1998

7. Unuigbe EI, Azubike CO, Eregie A.: Assessment for markers of nephropathy in newly diagnosed type 2 diabetics.West Afr J Med. 2005 Apr-Jun;24(2):134-8.

8. Velvet VF, Jaime TG. Diabetes Mellitus una enfermedad cardiovascular. Revista costarricense de cardiología. Vol 4, N1, abril 2002.

9. Wingard DL, Barrett-Connor EL, Scheidt-Nave C, McPhillips JB Prevalence of cardiovascular and renal complications in older adults with normal or impaired glucose tolerance or NIDDM. A population-based study.Diabetes Care. 1993 Jul;16(7):1022-5.